Press releases

Eevia Health Plc being followed by Analyst Group

Analyst Group Initiates equity research Coverage of Eevia Health Plc, ("Eevia" or "The Company").

The financial analyst Rosan Tekin and the equity research firm Analyst Group started tracking Eevia and issued a first equity analysis report last week. The report can be found here:

https://www.analystgroup.se/wp-content/uploads/2022/06/Analyst-Group-Eevia-Health.pdf

Analyst Rosan Tekin summarized the investment case:

"Eevia Health offers organic plant extracts for food nutraceuticals, drinks, and cosmetics under different brands. The Company is at a stage where it aims to increase production capacity, focus on higher-margin extracts, and develop new proprietary ingredients targeting eye disorders, which could be strong value drivers ahead. Having a broad product portfolio and high demand from customers, Eevia Health is entering a fast-growth phase, where an EBIT of EUR 4.8m is estimated in 2026. Based on an applied EV/EBIT multiple of 5x on estimated EBIT, and a discount rate of 14%, this yields an equity value per share of SEK 8.8 in a Base scenario. In conclusion, we see several drivers as well as market trends in Eevia's favor, and where steps in the right direction should reduce the current valuation discount."

The Analyst Group comment related to Eevia Health Plc is made on their behalf. Readers may assume that Analyst Group has received compensation for making the comment, but Eevia has not had any opportunity to influence the parts where Analyst Group has had opinions about the Company, future valuation, or anything else that could be considered a subjective assessment.

For further information, please contact:

Stein Ulve, CEO, Eevia Health Plc                          
Email: stein.ulve@eeviahealth.com                      
Telephone: +358 400 22 5967                  

INFORMATION ABOUT EEVIA HEALTH PLC

Eevia Health Plc, founded in March 2017, addresses significant health problems with bioactive compounds extracted from plant materials. The materials are primarily wild harvested from the pristine Finnish and Swedish forests near or above the Arctic Circle. The extracts are sold B2B as ingredients to dietary supplements and food brands globally. These global brands utilize the ingredients in their consumer product formulas.

Eevia Health is a manufacturer of 100% organically certified plant extracts. Although a significant product, Elderberry extract, is made from cultivated berries, most of Eevia's other raw materials, such as bilberry, lingonberry, chaga-mushroom, and pine bark, are wild-harvested in a sustainable fashion.

Eevia Health operates a modern green-chemistry production facility in Finland. Manufacturing natural ingredients near the raw material harvest areas, Eevia offers a short value chain with an environmentally friendly carbon footprint, competitive pricing, and extreme transparency. Eevia listed its shares at Spotlight Stock Market in Sweden in June 2021, with the short name EEVIA.

To learn more, please visit  www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth. 

INFORMATION ABOUT ANALYST GROUP AB

About Analyst Group: One of Sweden's fastest growing equity research boutiques with a focus on small and medium-sized listed companies.

Read more about Analyst Group here: Startsida - Analyst Group

2022-11-30

Eevia Health Plc, ("Eevia" or "The Company"), has re-established its Kosher certification. The Jewish Community of Helsinki has validated Eevia's Kosherization and certified the Kosher and Parve status of the company products.

2022-11-25
Regulatory

Eevia Health Plc ("Eevia" or "The Company") is releasing its quarterly financial report for the third quarter of 2022.

2022-11-22
Regulatory

Eevia Health Plc ("Eevia" och "the Company") announces today the outcome of the Rights Issue, whose subscription period ended on November 15, 2022, where a total of 14 376 015 shares, corresponding to 100 percent of the offered shares, have been allocated. 9 233 685 shares (64 percent) were subscribed with subscription rights, and 5 142 330 shares (36 percent) were subscribed without subscription rights, corresponding to 100 percent of the Rights Issue. Through the Rights Issue, the Company will raise proceeds of approximately SEK 21.6 million before deducting costs related to the Rights Issue. No guaranteed commitments have been utilized.  

2022-11-18
Regulatory

To timely secure raw materials for its recent order intake of large quantities of bilberry products, Eevia Health Plc ("Eevia" or "The Company") has secured a short-term loan of NOK 2 million from its largest shareholder, Betulum AS (Norway).

2022-11-09
Regulatory

Following a successful exhibition at the Supply Side West trade show in Las Vegas, US, last week, Eevia Health received a start order for its new cognitive health product, the Feno-Cerasus™, for SEK 223k. The new product was launched last week and is a standardized anthocyanin extract from tart cherry (Prunus Cerasus). Eevia Health focuses on the cognitive effects of the latest product, including sleep quality and quantity, memory, stress, and cortisol levels.

2022-11-08
Regulatory

Following a successful exhibition at the Supply Side West trade show in Las Vegas, US, last week, Eevia Health ("Eevia" or "The Company") received an order for the Feno-Sambucus™ equaling a revenue of SEK 34.4 million. The order is a new contractual volume section related to a five-year Sales Agreement with a US brand owner. The new section has adjusted prices and terms.

2022-11-03
Regulatory

Eevia Health has developed a new plant extract with product benefits for cognitive health and improved sleep. The new product, Feno-Cerasus™, is launched today at a major trade show in Las Vegas, US, the Supply Side West. The new ingredient is a standardized anthocyanin extract from tart cherry (Prunus Cerasus). Eevia Health focuses on the cognitive effects of the new products, including sleep quality and quantity, memory, as well as stress, and cortisol levels.

2022-11-03

Eevia Health is presenting its branded ingredients at a major trade show for the nutraceutical industry, SupplySide West, which takes place in Las Vegas, USA this week. This trade show is co-organized with Food ingredients North America and is the premier gathering of health & nutrition professionals bringing together buyers and suppliers from throughout the industry. SupplySide events are all about the science and strategy around the development of products driving the global business economy. 

2022-10-20

The Board of Directors of Eevia Health Plc ("Eevia" or the "Company") has today decided on a rights issue with preferential rights for Eevia's existing shareholders ("Rights Issue"). The target amount is approximately SEK 21.6 million. The proceeds shall primarily finance sales and marketing efforts and increase working capital. About 82 percent of the Rights Issue is covered by subscription and guarantee commitments.

1
2
...
7
>>